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Background/aim: Oncometabolites provide a new approach towards the diagnostics and prognosis of the clinical progress of prostate
cancer (PCa). This study is about the diagnostic and predictive value of a panel of urinary oncometabolites (ethanolamine, kynurenine,
β-alanine, α-alanine, leucine, isoleucine, γ-aminobutyric acid, and sarcosine) and correlation with prostate-specific antigen (PSA) and
Gleason score in patients diagnosed with prostate cancer.
Materials and methods: The participants in this cross-sectional study were divided into PCa group (101 patients who matched the
including criteria, average age 71) and control group (52 individuals, with no evidence of malignancy, without oncological and other
chronic diseases, and without prostate gland pathology, average age 40). The criteria to be included in the PCa group were as follows:
i) being diagnosed with prostate cancer, based on digital rectal examination (DRE), prostate ultrasound investigation, or biopsy; ii) not
being subjected to a surgical or any other treatment; iii) not having any other concomitant oncological diseases, renal failure, diabetes
mellitus. The urinary concentration of the selected metabolites was established through high-performance liquid chromatography with
tandem mass spectrometry detection (HPLC-MS/MS).
Results: The comparison of both groups established a significantly different elevated concentration of ethanolamine, sarcosine and
kynurenine, and a significantly different decreased concentration of β-alanine and isoleucine in PCa group. No changes of the values
were detected in the PCa group with PSA levels below and above 10 ng/mL and Gleason score below and above 6 (p > 0.05). To
test whether combination of several variables is more powerful in discriminating between PCa and control group multiple logistic
regression analysis was performed. A model including ethanolamine, sarcosine, kynurenine, β-alanine, and isoleucine demonstrated
negative predictive power (NPP) 76.2% and positive predictive power (PPP) 81.8%.
Conclusion: Urinary concentrations of ethanolamine, sarcosine, kynurenine, β-alanine, and isoleucine in PCa group differ significantly
from that of control group. New expanded population studies are needed to discuss our results.
Key words: Prostate cancer, oncometabolites, biomarkers, liquid chromatography with tandem mass spectrometry

1. Introduction
Prostate cancer (PCa) falls within the top 10 of malignant
diseases on a global scale, and it is the second most
diagnosed cancer in men; it ranks the fifth among the
causes of cancer-related deaths in men worldwide [1, 2].
The growing body of evidence suggests that a great part of
the patients with a high-risk disease are not treated, which
leads to a further and more expensive therapy for the more
advanced or metastatic forms.
The PCa morbidity rate is expected to continue to rise
due to demographic changes, but the improved approach

for treating the disease would benefit the results while
lowering the therapy costs at the same time. Nonspecific
or missing symptoms often lead to a delayed diagnosis
when treatment is already ineffective, and, therefore, the
development of efficient and specific methods for screening
and early detection of PCa is extremely important [3].
The symptoms of a locally advanced or metastatic PCa
include nonspecific symptoms of the lower urinary tract,
which may be associated with benign prostate hyperplasia
as well. To this date, digital rectal examination (DRE) and
prostate specific antigen (PSA) are the most commonly
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used methods for early detection, but they cannot predict
the clinical progression. Since PSA has a low specificity
and is associated with a high number of false-positive
results, each induration and nodule formation of the
prostate gland, as well as high PSA values, suggest a further
assessment through biopsy or imaging diagnostics [3].
For men diagnosed with PCa, there are various
algorithms and nomogrames, which are able to predict the
probable clinical outcome based on tumor pathology and
PSA levels. Even though these methods work relatively
well, there is a significant difference in the outcome for
males in the groups with low- and high-risk spectrum. On
the one hand, 30-50% of the males, identified as low-risk,
will need treatment, while for the high-risk patients with
Gleason score 8–10, the PCa mortality within a 15-year
range could be lower than 40% [4, 5]. These limitations of
the current approaches have led to an increased focus on
molecular biomarkers with the aim of improving the PCa
detection and individual prognosis stratification or the
risk of progression. Individual metabolic characteristics
of the prostate gland have been known for a long time,
but the compilation of a more extensive metabolomic
profile of PCa is still at a very early, barely inceptive stage.
During the last decade, metabolomics has established
itself as a new and promising method associated with
PCa biomarkers detection. Metabolomic studies could
encompass a specific analysis of a single or a small group of
metabolites, linked to a specific metabolic pathway. These
metabolites could be an indicator for separate functional
disorders in the metabolic pathways, affected by various
pathological conditions, including those of PCa patients
as well [6,7]
Numerous studies have reported the identification of
potential biomarkers, capable of differentiating between a
benign and malignant prostate tissue. Fernández-Peralbo
et al., [8], have conducted a nontargeted metabolomics
urinary analysis of 62 patients with clinically significant PCa
and 42 healthy individuals, with both groups confirmed via
biopsies. Twenty-eight significant metabolites have been
established and proposals have been made for compiling
an analytical model, characterized with 88% sensitivity and
93% specificity. Sreekumar et al., [9] metabolomic study
of amino acids in the urine of biopsy-positive and biopsynegative patients single out sarcosine, a glycine metabolite,
as a potential PCa biomarker. The study has been widely
discussed and interpreted as a demonstration that urinary
sarcosine could be used as a promising biomarker for early
detection or prognosis. Currently, the role of sarcosine as
a PCa biomarker is still debatable. The studies of Colleselli
et al. [10] and Cao et al., [11] support this theory. Other
authors reject Sreekumar’s thesis and claim that urinary
sarcosine could not be used for diagnosing prostate cancer
and identifying aggressive tumors [12]. Other studies have
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found statistically significant differences in terms of leucine,
isoleucine, kynurenine, uracil, and γ-aminobutyric acid
(GABA) in patients with PCa and a control group without
prostate gland pathology, when analyzing urine and
plasma [13]. The most recent findings of tissue and urine
metabolites with potential for prostate cancer biomarkers
were summarized and discussed in a recently published
paper. The review unveiled that the development and
progression of PCa are mainly associated with alteration
of amino acid metabolism, energy metabolism, and
membrane metabolism. In the reviewed papers, not only
one compound is outlined as a possible biomarker. Multibiomarker panel has the advantage to capture more deeply
various metabolic dysregulations occurring in cancer
development and progression than a single biomarker does
[14]. The diagnostic variations, including instrumental,
imaging, biochemical, genetic, and immunohistological
tests give rise to an increased interest in the discovery and
study of new biomarkers in different biological matrices
that would improve both the early detection of the disease
and would act as predictors for its clinical aggressiveness
and the success of the treatment as well.
The aim of this study was to evaluate the diagnostic and
predictive value of sarcosine, included in a panel of urinary
oncometabolites (alanine, β-alanine, ethanolamine,
GABA, kynurenine, leucine, and isoleucine) and their
correlation with PSA and Gleason score in patients,
diagnosed with prostate cancer.
2. Materials and methods
2.1. Patients
All the procedures of the study involving human
participants were performed in accordance with the ethical
standards of the Institutional and National Research
Committee and within the 1964 Helsinki Declaration and
its later amendments or comparable ethical standards. The
study design was approved by the Ethics Committee of the
Medical University of Plovdiv, Bulgaria (No 6/23.11.2017).
The protocol was conducted in accordance with the
Helsinki Declaration, Good Clinical Practice guidelines,
and national laws. All the procedures were conducted after
obtaining written informed consent.
This cross-sectional study was conducted from
January 2019 to July 2020 at the Urology Clinic of St.
George University Hospital, Plovdiv, Bulgaria. The criteria
for including patients into the prostate cancer group
were as follows: i) being diagnosed with prostate cancer,
based on digital rectal examination (DRE), prostate
ultrasound investigation, biopsy, ii) not being subjected
to a surgical or any other treatment, and iii) not having
any other concomitant oncological diseases, renal failure,
and diabetes mellitus. During this period, 328 men with
prostate cancer were examined in the clinic, 148 of which
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were previously diagnosed with PCA and had received
any treatment. These patients were excluded from the
study. The prostate cancer of the other 180 patients was
diagnosed based on increased PSA levels and first biopsy
without any previous blood tests for PSA levels and
biopsies. These patients were not subjected to a surgical
or any other treatment. Fifty-seven out of 180 patients
were not included in the study because of the concomitant
oncological or chronic diseases such as renal failure and
diabetes mellitus. There were 22 patients who refused to
sign in written informed consent for religious or ethical
reasons. Thus, the PCa group consists of 101 patients not
subjected to a surgical or any other treatment (average
age 71 (56–87) years). The control group includes 52 men
showing no evidence of malignancy without oncological
and other chronic diseases and not having prostate gland
pathology (average age 40 (28–57) years). They all have
been examined for other urological diseases and also
signed written informed consent.
2.2. Chromatographic analysis
Patients’ medium portion of the first-morning urine has
been collected in a sterile container, centrifuged, frozen at
–70 °C, and stored until analysis.
The listed metabolites were analyzed through a highperformance liquid chromatography method with tandem
mass spectrometry (HPLC-MS/MS). The detection ranges
are as follows: sarcosine 0.004–0.500 mg/L; β-alanine,
GABA and isoleucine 0.078–10.00 mg/L; isoleucine 0.156–
20.000 mg/L; alanine, kynurenine, and ethanolamine
0.78–100.000 mg/L. A brief description of the method is as
follows: On the day of analyses, urine sample was thawed,
centrifuged, diluted 2 times, and subjected to derivatization
with danzylchloride at pH = 9.5 (0.5 M NaHCO3) for
15 min at 25 °C. At the end of the reaction time, 15 µL
10% solution of methanoic acid were added to stop the
reaction. The solution was diluted 100-fold and injected
in the Dionex /Thermo UltiMate 3000 chromatographic
system (Thermo Fischer Scientific, MA USA) equipped
with Accucore reversed-phase mass spectrometry (100mm
× 2.1mm, 2.6 µm) column (Thermo Fischer Scientific,
MA USA). Gradient elution was performed with phase
A (0.1% НСООН in water) and phase B (0.1% НСООН
in 60% CH3CN) with flow rate 0.1 mL/min. Autosampler
temperature was 4 °C, and volume of injection was 10
µL. Analytes were detected with Thermo TSQ Quantum
Access Max triple quadrupole mass spectrometer operated
in positive ion mode using electrospray ionization (ESI)
within the following conditions: spray voltage 3500V,
evaporation temperature 300 °C, capillary temperature 200
°C, sheath gas (N2) pressure 45 units, collision gas (Ar) 1.5
mTorr. Analytes were detected through the transition of
the molecular ion to the production at the corresponding
retention times. Their concentration was back-calculated

by using calibration curves prepared in pooled urine
samples. The results were registered and processed with
Xcalibur software (Thermo Fischer Scientific, MA USA)
in SRM mode.
2.3. Statistical analysis
The data were analyzed with descriptive statistics,
Kolmogorov–Smirnov normality test and nonparametric
test using GraphPadPrism 9.0.0 version (GraphPad
Software, 2365 Northside Dr.Suite 560, San Diego, CA
92108, USA). The binary comparison continuous data was
analyzed with Mann–Whitney U test. The comparison
among three groups (low, middle, and high risk) was done
with Kruskal–Wallis test and Dunn’s post hoc test. ROC
curve analysis was done for investigating the diagnostic
potential of the metabolites with elevated or reduced
concentrations with a statistical difference in both groups:
sarcosine, β-alanine, ethanolamine, GABA, kynurenine,
and isoleucine. To test whether the combination of several
variables is more powerful in discriminating between PCa
patients and the control group, multiple logistic regression
analysis (Hosmer–Lemeshow tets) was performed,
and multivariable ROC curves were build. The level of
significance of 5 % probability (p < 0.05) was adopted.
3. Results
The group of PCa patients includes 101 cases, histologically
verified via biopsy, Gleason score, PSA test and ultrasound
examination of the urinary tract system but not subjected
to a surgical or any other treatment. The average PSA level
was 22.73 ng/mL, and median Gleason score was 7. The
concentrations of all metabolites were determined in both
PCa (n = 101) and control group (n = 52). Urinary samples
from all patients were subjected to a chromatographic
analysis. The results were normalized in relation to
creatinine, determined by the Jaffe method (15). The
comparison of the results has been made with a MannWhitney U test and has established a significant difference
in ethanolamine (6.77 PCa group vs 4.88 control group,
p = 0.044), sarcosine (0.146 PCa group vs 0.105 control
group, p = 0.003), kynurenine (0.940 PCa group vs 0.522
control group, p<0.001), β-alanine (0.294 PCa group vs
0.486 control group, p = 0.045) and isoleucine (0.755 PCa
group vs 0.952 control group, p = 0.042) (Figure 1). The
concentration of metabolites were also compared within
the PCa group and the patients were divided into such
with Gleason score up to (n = 47) and above 6 (n = 54),
and PSA values up to (n = 42) and above 10 ng/mL (n =
59). No changes of the values of the studied metabolites
were detected in the group with verified prostate cancer
with PSA levels below and above 10 ng/mL (p > 0.05).
Statistically significant changes have not been found in the
values of the studied metabolites in patients with verified
prostate cancer, stratified in terms of Gleason score (GS)
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4. Discussion
The characterization of metabolites, derived through
specific processes in cancer cells or as a result of metabolic
pathway disorders, is a strategy for the discovery of new
methods for early detection of pathological changes
in the prostate gland and the study of prostate cancer
progression. Many studies were conducted in an attempt
to evaluate the role of amino acids as metabolites with
potential as prostate cancer biomarkers. Prostate cancer
was studied using metabolomics profiling in order to get
insight into the entire measurable metabolome. There are
a few studies that are focused on targeted metabolites [16,
17]. Out of numerous analytes studied in urine, plasma,
and prostate tissue via biopsy, ethanolamine, sarcosine,
β-alanine, alanine, kynurenine, GABA, isoleucine, and
leucine are found to be suitable for compiling a panel for
prostate pathological changes, so the present study focuses
on these 8 metabolites.
Since the number of samples analyzed in our study
is limited (101 prostate cancer patients and 52 controls),
it should be considered as a pilot study. The presented
research gives the opportunity to see the outcomes of
previous studies on amino acid profile changes in prostate
gland cancer [14, 18, 19] and also provides new data on the
levels of some other amino acids and metabolites, which
are not so well examined in prostate cancer biomarker
investigations such as ethanolamine, kynurenine,
isoleucine, and β-alanine. However, only sarcosine is
currently studied for its potential role in prostate cancer
progression.
Urine has been selected as biological matrix due to the
noninvasive sampling method, easy further processing,
and high metabolite content. Urine samples from 52
controls and 101 prostate cancer patients were analyzed
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ng/mL- r = –0.15, r = –0.26 and r = –0.11 respectively.
Only GABA shows very weak correlation with PSA in the
group with PSA ≥ 10 mg/mL r = 0.1.
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= 47) and above 6 (n = 54) (ethanolamine p =
0.627, β-alanine p = 0.278, alanine p = 0.241, GABA0.5p =
0.288, sarcosine
p = 0.260, kynurenine p = 0.623, isoleucine
5
p = 0.367 and leucine p = 0.353). For that reason, patients
0.0
were divided in three subgroups: low risk: PSA<10 ng/mL,
GS<7 (n0 = 38); middle risk: PSA 10-20 ng/mL, GS=7 (n =
36) and high-risk PSA>20 ng/mL, GS>7 (n = 27) according
to the EAU recommendations [2]. From all the investigated
metabolites only γ-aminobutyric acid (GABA) levels were
found to be statistically different elevated in the high-risk
group compared to both middle and low risk groups: high
risk vs low risk p = 0.045; high risk vs. middle risk p =
0.025 (Figure 2).
For the metabolites with statistically significant
difference in concentrations ROC analysis was performed.
The AUC varies between 0.60 and 0.72 (Table 1). Results
revealed the kynurenine presented the highest significant
diagnostic value (AUC: 0.72, sensitivity 70%, specificity
65.4% p<0.001), followed by sarcosine (AUC: 0.64,
sensitivity 71.3%, specificity 50% p = 0.003).
Ability of a panel of metabolites to discriminate the
healthy individuals from PCa patients was assessed with
multiple logistic regression analyses. The multivariable
ROC curve’s area under curve (AUC) increases with the
number of included variables (Table 2). The negative
predicted power (NPP) and positive predicted power
(PPP) of models are as follows: kynurenine/isoleucine
model has NPP 68.3% and PPP 78.4%; ethanolamine/
kynurenine/isoleucine model-NPP 71.4% and PPP 80%;
kynurenine/β-alanine/isoleucine model-NPP 72.7% and
PPP 80%; sarcosine/kynurenine/β-alanine/isoleucine
model- NPP 73.7% and PPP 81.5%; ethanolamine/
sarcosine/kynurenine/β-alanine/isoleucine model- NPP
76.2% and PPP 81.8%.
The Spearman correlation between oncometabolites
and PSA levels was studied only in PCa group. A very weak
negative correlation was found between etanolamine,
GABA and kynureniene and PSA in group with PSA<10
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Figure 2. Median values with 95% confidence interval of GABA
in patients with high, middle, and low risk of the PCa group.
*statistically significant difference between median values.

with HPLC-MS/MS method. The obtained results proved
that prostate cancer causes changes in five of the studied
metabolites. Significantly higher median values are
observed for ethanolamine (6.773, p = 0.044), sarcosine
(0.146, p = 0.003) and kynurenine (0.940, p < 0.001) in
PCa group compared to the controls, while β-alanine
and isoleucine show significantly lower median values
compared to the controls (0.294, p = 0.048 and 0.755, p =
0.042 respectively), (Figure 1).

Sarcosine, also known as N-methylglycine is
an intermediate product of the amino acid glycine
synthesized by glycine-N-methyltransferase. The
predictive role of sarcosine was discussed for the first
time in the study of Sreekumar et al., [9]. The authors
focus on the potential of the molecule panel within the
sarcosine metabolic pathway to provide biomarkers for
understanding the biology of PCa. The study includes
independent metabolomic profiling through liquid
chromatography/gas chromatography mass-spectrometry,
detecting six metabolites, the levels of which were higher
in tumor progression when compared to benign prostate
tissue, adjacent to a tumor tissue, and in comparison to
a localized PCa and metastatic PCa. Those metabolites
are sarcosine, uracil, kynurenine, L-leucine, proline, and
glycerol-3-phosphate. Among them, sarcosine has shown
the most prominent differences. The same authors found
that sarcosine is a potential mediator of PCa progress. The
metabolomic profile of the progressing PCa identifies the
gradually increasing sarcosine level in metastatic PCa,
as well as a moderate but significant increase in the level
of the metabolite in urine in verified PCa. Other authors
reported different findings of sarcosine concentration
in urine and do not confirm its role in early detection
and clinical progress of prostate cancer [10]. Our results
confirm significantly different sarcosine concentration in
the urine of both groups (Figure 1a).

Table 1. Area under the curve (AUC), 95% confidence intervals (CI) and p values for ethanolamine, sarcosine,
kynurenine, b-alanine, and isoleucine.
Metabolites

AUC

95% CI

Cut-off
values

Sensitivity, %

Specificity,%

p

Ethanolamine

0.599

0.507–0.690

5.552

58

56

0.044

Sarcosine

0.645

0.552–0.737

0.100

71.3

50

0.003

Kynurenine

0.719

0.638–0.800

0.648

70

65.4

<0.001

β-Alanine

0.597

0.497–0.696

0.460

74.3

54

0.049

Isoleucine

0.600

0.503–0.697

0.914

66.3

56

0.042

Cut-off values are given in mg/g creatinine.
Table 2. Area under the curve (AUC), 95% confidence interval (95% CI), p values.
Model

AUC

95% CI

p

Kynurenine+Isoleucine

0.802

0.730–0.873

<0.0001

Ethanolamine+Kynurenine+Isoleucine

0.813

0.744–0.883

<0.0001

Kynurenine+β-Alanine+Isoleucine

0.832

0.767–0.898

<0.0001

Sarcosine+Kynurenine+β-Alanine+Isoleucine

0.848

0.785–0.912

<0.0001

Ethanolamine+Sarcosine+Kynurenine+β-Alanine+Isoleucine

0.860

0.799–0.921

<0.0001
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Ethanolamine is a degradation product of phospholipid
membranes, and it is involved of serine metabolism. It is not
an amino acid, but a primary amine and a primary alcohol.
Its presence in urine can be indicative for significant
processes in the human body like cellular proliferation
apoptosis, and enzyme activity. The concentration of
ethanolamine is significantly higher in the urine of
PCa patients (median value 6.773, p = 0.044) (Figure
1b), while Derezinski et al. [18] and Swanson et al. [19]
reported lower levels of its concentration in PCa patients
vs. controls. The elevated concentration of ethanolamine
might be associated with extreme cellular proliferation of
tumor cells and the aggressiveness of cancer.
In the current study, α-alanine and β-alanine were
included as isomers of sarcosine. The objective was to
separate them from sarcosine in order to determine
their precise concentration in the biological matrix. This
was cited as a drawback in previous studies in which an
elevated concentration of sarcosine might have been
due to simultaneous elution of sarcosine and its isomers
from the chromatographic column [20]. We were able to
successfully separate the three isomers and established a
significantly lower concentration of β-alanine in patients
with PCa (Figure 1c). There is limited data on the role of
β-alanine in the development and progression of PCa,
which needs further elucidation. A study conducted by
Derizinski et al. [18] did not detect significantly different
changes in the levels of β-alanine in urine and serum of
prostate cancer patients compared to the control group of
healthy individuals.
Compared to the control group, a significantly higher
kynurenine concentration was found in the PCa group
(Figure 1d). Metabolites of the kynurenine pathway
have been reported to increase during the development
of prostate cancer [9, 16, 17]. The presented data are in
accordance with a previous study by Sreecumar at al. [9]
who found increased kynurenine concentration in urine.
Kynurenic acid (metabolite of the kynurenine pathway)
was also found to increase in the urinary samples of 32
patients with PCa before radical prostatectomy and the
samples of 101 patients with increased PSA values before
an ultrasound-guided biopsy [17]. However, the analysis
showed that sarcosine and kynurenic acid do not have any
diagnostic value. Univariate ROC curve analyses of our
results revealed that the kynurenine presented the highest
significant diagnostic value (AUC: 0.719, p < 0.0001),
followed by sarcosine (AUC: 0.645, p = 0.003) (Table 1.).
Isoleucine is a part of the group of branched–chain
amino acids together with leucine and valine. Our findings
on significantly lower concentrations of isoleucine in PCa
group are consistent with the results of Derezinski et al.
[18], who found a decreased urine and serum level of
isoleucine in the case of prostate cancer (Figure 1e). The
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diagnostic ability of all five metabolites is higher than the
adopted level of significance but AUC is still low than
0.750.
In the group of prostate cancer additional analyses
were performed in order to establish whether there were
statistically significant changes in the concentrations of
studied metabolites. PSA values from 4 to 10 ng/mL are
included in the so-called grey area, within which the causes
of the increase could be due not only to malignant diseases
but to benign changes and prostatitis as well. In a great
number of cases, PSA values up to 10 ng/mL in patients
with verified PCa is associated with an earlier stage of the
disease, better therapeutic options, and a more favorable
outcome, while values above 10 ng/mL are associated with
more advanced processes and worse prognosis. Therefore,
the joint study of both PSA values and metabolite
concentrations in patients with verified prostate cancer
would give a better view on the malignant potential and
prognosis for the tumor. The weak correlation between
metabolites and PSA levels indicates that its level may not
strongly affect metabolism of amino acids.
Gleason score is used as a method for histological
differentiation of tumors, clinical course of the disease
and prognostic group. Men with higher Gleason score
fall in a group with poorer prognosis, their carcinomas
are less differentiated, more aggressive, and with worse
outcome. Elevated γ-aminobutyric acid concentration can
be associated with worse prognosis for patients with GS>7
and PSA>20 ng/mL and higher risk of organ metastases.
The utility of panel of metabolites to discriminate
the samples with high accuracy was demonstrated by
Derezinski et al., [18]. The panel including 5 metabolites
showed 78% predictive accuracy. The multiple logistic
regression models including two, three, four, and five
metabolites were analyzed, and multivariable ROC curves
were built. The models presented in Table 2 demonstrate
the highest AUC and increased NPP and PPP. Kynurenine
and isoleucine are present in all models whereas sarcosine
is present in only two of them. These findings allow
proposing future directions of research – special attention
should be paid to kynurenine and isoleucine. The example
of ethanolamine, β-alanine, and sarcosine indicated that
nonproteinogenic amino acids and other metabolites
can contribute to prostate cancer pathogenesis and
improvement of its detection. Metabolomic analyses have
outlined other amino acids that have statistically different
concentrations in healthy individuals and prostate cancer
patients which opened the gate for future analyses of other
panels of metabolites in order to find the best model for
detection, and diagnostic and prognostic of the disease.
One of the limitations of our study is the absence of
demographic data. On the other hand, the control group
was recruited from individuals presenting for other
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etiologies and these patients are much younger than
patients in the PCa group. In addition, some of the selected
metabolites are still in the early stages of investigation as
potential biomarkers and our results need to be verified in
larger studies and other population groups.
The present study focuses on metabolites with an
established role in the pathogenesis of PCa cancer
(sarcosine) as well as some amines and amino
acids, which have been recently outlined as possible
biomarkers. To the best of our knowledge, this panel
has not been studied by the other authors. It outlined
several metabolites (ethanolamine, β-alanine, sarcosine,
isoleucine, GABA, kynurenine) with significant changes
in their concentrations which need further investigation.
The proposed model for discriminating PCa and control
group, which includes ethanolamine, β-alanine, sarcosine,

kynurenine, and isoleucine could be used for urinary
metabolite determination for possible early cancer
detection and these five metabolites could be used as
biomarkers.
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